Cannabinoid Receptors as Therapeutic Targets

Author(s): Alexandros Makriyannis, Spyros P. Nikas, Ganesh A. Thakur, Spiro Pavlopoulos.

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 14 , 2006

Submit Manuscript
Submit Proposal

Abstract:

The cannabinoid receptors CB1 and CB2 are family A, G-protein Coupled Receptors that mediate the effects of cannabinoids, a class of compounds that are so named because the first members were isolates of the cannabis plant. In recent history, there has been much anecdotal evidence that the potent and diverse physiological responses produced by these compounds can be turned to therapeutic benefit for a wide variety of maladies. The remarkable abundance of cannabinoid receptors and the discovery of several endogenous ligands along with enzyme and transporter proteins for which they are substrates, suggests that an endogenous cannabinoid neuromodulatory system is an important mediator of biological function. For these reasons CB1 and CB2 receptors are attractive targets for the design of therapeutic ligands. The action of these receptors, however, may also be modulated by manipulating the enzymes and membrane transporters that regulate the endogenous ligands. Despite the range of physiological processes and activities that are mediated by cannabinoid receptors, it is clear that it is possible to produce ligands that result in differential responses. In this paper, we review the pharmacophoric elements that lead to these differential responses and in order to discuss them in context we present an overview of structural aspects governing cannabinoid receptor function, the cannabinergic system and its physiological functions.

Keywords: Cannabinoid, pharmacophore, aminoalkylindoles, diarylpyrazoles, endocannabinoids, receptor, selectivity, agonist, antagonist

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 14
Year: 2006
Page: [1751 - 1769]
Pages: 19
DOI: 10.2174/138161206776873743
Price: $58

Article Metrics

PDF: 6